9
Participants
Start Date
August 31, 2014
Primary Completion Date
June 30, 2015
Study Completion Date
July 31, 2015
Saracatinib
Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
University of Cincinnati, Cincinnati
Baylor College of Medicine, Houston
University of Texas Health Science Center-Houston, Houston
University of Texas
OTHER
University of Cincinnati
OTHER
Tony Eissa
OTHER